Preclinical results of Avila Therapeutics' AVL-181 and AVL-192 presented at EASL Annual Meeting

Apr 16 2010

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on two of its Hepatitis C Virus (HCV) protease inhibitors, AVL-181 and AVL-192. These inhibitors, due to their unique mechanism of action with superior selectivity and potency, have potential as best-in-class, pan-genotype HCV therapeutics. New data on both drugs were presented today at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL).

“We believe that our drugs, through their unique covalent mechanism, have the ability to offer a profile for a best-in-class pan-genotype HCV therapeutic. We envision that these therapies could be the backbone of a new standard of care for HCV”

AVL-181 and AVL-192 are novel, orally-available compounds that can rapidly and completely silence the HCV protease (also known as NS3) through highly selective, irreversible covalent bonding to the target protein. Clinical investigation of AVL-181 is anticipated to begin in 2010. Preclinical data have demonstrated that each drug achieves high potency and selectivity and also effectively inhibits drug-resistant mutations of HCV protease. In addition, AVL-192 has shown unusually high potency by demonstrating the ability to clear replicon cells as a monotherapy in vitro.

"We believe that our drugs, through their unique covalent mechanism, have the ability to offer a profile for a best-in-class pan-genotype HCV therapeutic. We envision that these therapies could be the backbone of a new standard of care for HCV," said Juswinder Singh, Ph.D., Chief Scientific Officer, Avila.

In a poster titled, "AVL-192: Potency Against HCV NS3 Mutants Allows for Replicon Clearance as a Monotherapy and in Combination Studies," (Poster #751) preclinical data demonstrate that AVL-192:

• Potently and irreversibly silences both wild-type (EC50, 3.7 nM) and clinically-arising HCV protease mutants (R155K EC50, 6.7 nM);
• Is highly selective and spares host proteases;
• Is curative as monotherapy in the genotype 1b replicon clearance assay at concentrations as low as 24 nM;
• Durably inhibits the HCV protease and drug resistant mutants for more than 24 hours after a single exposure; this contrasts with the need for nearly continuous exposure required by the reversible HCV protease inhibitors currently in late-stage clinical trials.

In a second poster, "AVL-181, a Potent and Selective Irreversible HCV Protease Inhibitor, Exploits the Binding Site Microenvironment to Form a Targeted and Highly Specific Covalent Bond with CYS-159" (Poster #764), the data show that AVL-181:

• Forms an irreversible bond with Cys159, a non-catalytic amino acid that is present in all variants of HCV protease, thus facilitating pan-genotype activity;
• Achieves uniquely selective covalent bond formation with HCV protease because of a secondary interaction with an amino acid in the Cys159 microenvironment called Lys136. The Lys136 interaction enables use in AVL-181 of targeted chemistry that uniquely bonds to Cys159 in HCV protease and does not bond to human proteases.

SOURCE Avila Therapeutics, Inc.